Tepotinib is a type of inhibitor that targets the MET tyrosine kinase. It’s made for NSCLC patients who have a specific genetic change called MET exon 14 skipping mutation. It works by stopping the MET signaling process, which is really important in how NSCLC grows.
The drug comes in tablet form, with each one having 225 mg of tepotinib. For adults, the usual dose is 450 mg, taken once a day, and it’s best to take it with some food. The tablets come in bottles with 30 pills in each.
Using tepotinib as a treatment is a big deal for people with that type of NSCLC because it tackles a particular genetic issue that helps the cancer grow.
